Safety and Effectiveness of the MiniMed™ 780G System With DS5 CGM
a study on Diabetes Diabetes Type 1
- for people ages 7-80 (full criteria)
- at San Francisco, California and other locations
- study startedestimated completion
- Principal Investigator
- by Laya Ekhlaspour, M.D.
The purpose of this study is to confirm the safety and effectiveness of the MiniMed 780G insulin pump used in combination with the DS5 CGM in type 1 diabetes adult and pediatric subjects in a home setting.
Safety and Effectiveness Evaluation of the MiniMed™ 780G System Used in Combination With the DS5 CGM
This study is a multi-center, single arm study in insulin-requiring adult and pediatric subjects with type 1 diabetes on the MiniMed 780G system using DS5 as well as Medtronic Extended infusion set and reservoir. The run-in period and study period will be approximately 120 days long.
Type 1 Diabetes, Type 1 Diabetes Mellitus, Insulin, Insulin Pump with Continuous Glucose Monitoring
You can join if…
Open to people ages 7-80
- Age 7 - 80 years at time of screening.
- Has a clinical diagnosis of type 1 diabetes:
- 14 - 80 years of age: A clinical diagnosis of type 1 diabetes for 2 years or more as determined via medical record or source documentation by an individual qualified to make a medical diagnosis.
- 7 - 13 years of age: A clinical diagnosis of type 1 diabetes for 1 year or more as determined via medical record or source documentation by an individual qualified to make a medical diagnosis.
- Does not require a legally authorized representative to consent on their behalf due to mental or intellectual disability.
- Subject or parent/caregiver is literate and able to read the language offered in the pump or pump materials.
- Subject and/or legally authorized representative is willing to provide informed consent for participation.
- Is willing to perform fingerstick blood glucose measurements as needed.
- Is willing to wear the system continuously throughout the study.
- Must have a minimum daily insulin requirement (Total Daily Dose) of greater than or equal to 8 units.
Has a Glycosylated hemoglobin (HbA1c) less than 10% (as processed by Central Lab) at time of screening visit.
10. Has thyroid-stimulating hormone (TSH) in the normal range OR if the TSH is out of
normal reference range the Free T3 is below or within the lab's reference range and Free T4 is within the normal reference range.
11. Uses pump therapy for greater than 6 months prior to screening (with or without CGM
12. Is willing to upload data from the study pump, must have Internet access, and a
computer system, or compatible smartphone that meets the requirements for uploading the study pump.
13. Is willing to take one of the following insulins and can financially support the use
of insulin preparations as required by the study:
- Humalog (insulin lispro injection)
- NovoLog (insulin aspart injection)
- Admelog (insulin lispro injection)
You CAN'T join if...
- Has a history of 2 or more episodes of severe hypoglycemia, which resulted in any the following during the 6 months prior to screening:
- Medical assistance (i.e., Paramedics, Emergency Room [ER] or Hospitalization)
- Has been hospitalized or has visited the ER in the 6 months prior to screening resulting in a primary diagnosis of uncontrolled diabetes.
- Has had DKA in the last 6 months prior to screening visit.
- Will not tolerate tape adhesive in the area of sensor placement as assessed by a qualified individual.
- Has any unresolved adverse skin condition in the area of sensor placement (e.g., psoriasis, dermatitis herpetiformis, rash, Staphylococcus infection).
- Is female of child-bearing potential and result of pregnancy test is positive at screening.
- Is sexually active female of child-bearing potential and is not using a form of contraception deemed reliable by the investigator.
- Is female and plans to become pregnant during the course of the study.
Is being treated for hyperthyroidism at time of screening.
10. Has diagnosis of adrenal insufficiency. 11. Has taken any oral, injectable, or intravenous (IV) glucocorticoids within 8 weeks
from time of screening visit, or plans to take any oral, injectable, or IV glucocorticoids during the course of the study.
12. Is using hydroxyurea at time of screening or plans to use it during the study. 13. Is actively participating in an investigational study (drug or device) wherein he/she
has received treatment from an investigational study drug or investigational study device in the last 2 weeks.
14. Has used a MiniMed 780G pump prior to screening. 15. Is currently abusing illicit drugs. 16. Is currently abusing marijuana. 17. Is currently abusing prescription drugs. 18. Is currently abusing alcohol. 19. Using pramlintide (Symlin), DPP-4 inhibitor, liraglutide (Victoza or other GLP-1
agonists), metformin, canagliflozin (Invokana or other SGLT2 inhibitors) at time of screening.
20. Has a history of visual impairment which would not allow subject to participate in the
study and perform all study procedures safely, as determined by the investigator.
21. Has elective surgery planned that requires general anesthesia during the course of the
22. Has sickle cell disease, hemoglobinopathy; or has received red blood cell transfusion
or erythropoietin within 3 months prior to time of screening.
23. Plans to receive red blood cell transfusion or erythropoietin over the course of study
24. Is diagnosed with current eating disorder such as anorexia or bulimia. 25. Has been diagnosed with chronic kidney disease that results in chronic anemia. 26. Has a hematocrit that is below the normal reference range of lab used. 27. Is on dialysis. 28. Has serum creatinine of >2 mg/dL. 29. Has celiac disease that is not adequately treated as determined by the investigator. 30. Has had any of the following cardiovascular events within 1 year of screening:
myocardial infarction, unstable angina, coronary artery bypass surgery, coronary artery stenting, transient ischemic attack, cerebrovascular accident, angina, congestive heart failure, or ventricular rhythm disturbances.
31. Has had history of cardiovascular event 1 year or more from the time of screening
- a normal EKG and stress test within 6 months prior to screening or during screening or
- clearance from a qualified physician prior to receiving the study devices if there is an abnormal EKG or stress test.
- Has 3 or more cardiovascular risk factors listed below without a normal EKG within 6 months prior to screening or during screening or clearance from a qualified physician if there is an abnormal EKG:
- Age >35 years
- Type 1 diabetes of >15 years' duration
- Presence of any additional risk factor for coronary artery disease
- Presence of microvascular disease (proliferative retinopathy or nephropathy, including microalbuminuria)
- Presence of peripheral vascular disease
- Presence of autonomic neuropathy
- Is a member of the research staff involved with the study.
- Is a Medtronic Diabetes employee or their immediate family member (excluding adult children and/or adult siblings).
- University of California San Francisco (UCSF) The Madison Clinic for Pediatric Diabetes
not yet accepting patients
San Francisco California 94158 United States
- Diablo Clinical Research
accepting new patients
Walnut Creek California 94598 United States
- Stanford University
not yet accepting patients
Palo Alto California 94304 United States
Lead Scientist at UCSF
- Laya Ekhlaspour, M.D.
Assistant Professor, Pediatrics, School of Medicine. Authored (or co-authored) 43 research publications
- accepting new patients at some sites,
but this study is not currently recruiting here
- Start Date
- Completion Date
- Medtronic Diabetes
- Study Type
- Expecting 250 study participants
- Last Updated